Testing effectiveness (Phase 2)Enrolling By InvitationNCT07618624
What this trial is testing
BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression
Who this might be right for
Recurrent Head and Neck Squamous Cell CarcinomaHead and Neck Cancer
Sun Yat-sen University 42